Some really big movers this week, with a healthy rise from OPTI:Optibiotix helping erase a disastrous drop for SBTX:SkinBioTherapeutics. The deficit between cost and value narrowed by £4,455 to £92,726 and deficit between injection amount and value fell to £29.195. The total portfolio value increased to £113,082.
Biggest faller was SBTX:SkinBioTherapeutics which dropped a massive 30% after announcing a £5m convertible loan being used to make an acquisition. The market hated this, as these loans are usually related to death spiral funding. They could have waited for income from Croda before going on a spending spree. It remains to be seen whether the acquisition is a brilliant move or could cripple the company. The market thinks the latter.
RDT:Rosslyn Data dropped 10% but is 101% down so it doesn't make any difference.
IES:Invinity Energy dropped 5%, and again it didn't make any difference as these are already down 87%.
IGG:IG Group announced lackluster interim results, but I would argue with a P/E ratio of just 8 that this is already factored into the share price. They dropped 5% and I'm hoping it was a bit of a tree shake and we'll move up next week, especially as I recently doubled my holding.
BARC:Barclays climbed 6% and is only 10% down in my trading account. Usually something horrible happens just as it looks like these are about to get into profit.
POLY:Polymetal went up 6% but are still 75% down and no sign of them selling their Russian assets.
FXPO:Ferrexpo have been climbing well since re-instating the dividend and went up another 7% this week. They are still 82% down and no hope of getting anywhere near break-even until the Ukraine war is over.
IPX:Impax Asset Management have had a shaky few weeks, but climbed 8% this week to go back into potential profit.
AJB:AJ Bell have been on a real surge, and went up 10% this week so they are back in profit and 9% up. I still have one more monthly purchase to make in a few weeks which would normally make me want the price to stay low, but it shouldn't impact my potential profits too much if I buy 25% of my holding at a higher price.
OPTI:Optibiotix went up 10% and accounted for most of the gains. It turns out they have been tipped in the top 10 penny shares at weekend so someone possibly knew it was coming and made sure the price was jacked up before Monday. Let's hope enough people decide to buy in to add a few more pence.
PAF:Pan African Resources went up 10% and my holding is teetering on the verge of profitability.
TRX:Tissue Regenix issued a good trading update and the shares duly rose by 12%. They are still 60% down but I've never given up hope of these eventually coming good.
Share of the Week for the 2nd week in a row goes to CWR:Ceres Power which climbed 17% and is now only 21% down. I certainly timed my purchase of these really badly, but glad I bought back in as I've always liked them.
Here's the ISA and shares portfolio after week 26 of year 9.
| Weekly Change | |||
| Cash | £142.89 | -£3.90 | |
| Portfolio cost | £99,175.93 | +£0 | |
| Portfolio sell value (bid price-commission) | £52,188.90 | (-47.4%) | +£1,541.58 |
| Potential profits | £2,258.70 | +£514.73 | |
| Yr 9 Dividends | £202.72 | +£0 | |
| Yr 9 Interest | £3.29 | +£0 | |
| Yr 9 Profit from sales | £31.44 | +£0 | |
| Yr 9 proj avg monthly profit | £32.52 | (0.6%) | -£1.98 |
| Total Dividends | £12,114.15 | +£0 | |
| Total Interest | £5.22 | +£0 | |
| Total Profit from sales | £17,329.97 | +£0 | |
| Average monthly cash profit | £284.60 | (4.8%) | -£0.68 |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Compound performance | 41% | +0% |
Half way through Year 9 and things are looking a bit troubled, with the value down 47% of the cost price. However, 6 months ago that deficit was 58% so it's not as troubled. Value went up by £1,541 and GAW:Games Workshop returned to potential profit, but most of the £514 increase is my cheap OPTI:Optibiotix holding.
Feels like we've been quite flat for a while.
Still below the trend line but at least pointing towards it.
The SIPP looks like this after week 426 overall and week 10 of year 9.
| Weekly Change | ||||
| Cash | £147.82 | +£60.68 | ||
| Portfolio cost | £104,266.40 | +£0 | ||
| Portfolio sell value (bid price - commission) | £59,353.84 | (-43.1%) | +£2,938.52 | |
| Potential profits | £991.02 | +£142.41 | ||
| Yr 9 Dividends | £86.79 | +£0 | ||
| Yr 9 Interest | £1.10 | +£0 | ||
| Yr 9 Profit from sales | £3,373.97 | +£0 | ||
| Yr 9 proj avg monthly profit | £1,484.27 | (25.8%) | -£165.79 | |
| Total Dividends | £14,721.67 | +£0 | ||
| Total Interest | £7.03 | +£0 | ||
| Total Profit from sales | £14,209.87 | +£0 | ||
| Average monthly cash profit | £282.22 | (4.9%) | -£0.68 | |
| (Sold stocks profit + Dividends - Fees / Months) | ||||
| Compound performance | 40% | +0% |
A tax rebate increased cash by £60, and value went up nicely by £2,938. There are 7 holdings in potential profit and none are OPTI:Optibiotix so the £142 is spread among those. My cheapest OPTI holding is 9% down so it needs a few more good weeks before those get into profit. If I sell them I'd liberate around £1,500 and I'd almost certainly buy CAML:Central Asia Metals if I do, as it's a magic formula share and I want to significantly increase my SIPP holding.
A slightly sharper tick upwards in this account. I yearn to cross the injection line.
Not far from the trend line, but still below it.
The trading account looks like this after week 392 overall and week 28 of year 8.
| Weekly Change | |||
| Cash | £141.20 | +£0 | |
| Portfolio cost | £1,935.11 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,108.25 | (-42.7%) | -£24.36 |
| Potential profits | £0 | +£0 | |
| Year 8 Dividends | £8.56 | +£0 | |
| Year 8 Interest | £0 | +£0 | |
| Year 8 Profit | £283.99 | +£0 | |
| Yr 8 proj avg monthly profit | £45.27 | (+28.1%) | -£1.68 |
| Dividends | £68.66 | +£0 | |
| Interest | £0.03 | +£0 | |
| Profit from sales | -£646.70 | +£0 | |
| Average monthly cash profit | -£6.39 | (-4.0%) | +£0.02 |
| (Sold stocks profit + Dividends - Fees / Months) |
Unlike the other accounts, this one dropped despite a great week for BARC:Barclays, as it was a bad week for JLP:Jubilee Metals and a dreadful week for SBTX:SkinBioTherapeutics.
Slowly sliding despite BARC:Barclays looking promising
The trend line will soon be flat.
I've watched the Investor Meet presentation for SBTX:SkinBioTherapeutics and it has reassured me that things are on track, and that the current share price is very, very cheap. My new strategy is to go for risky shares in my ISA and so I may look at selling GAW:Games Workshop and PLUS:Plus 500 from my ISA. I also have £140 in my trading account so could add that to any SBTX purchase for a £0 rate commission, as it's in the same ISA. Assuming the SBTX price remains crippled on Monday I could get a bargain. On the other hand I could lose a load of cash. We'll soon see.
No comments:
Post a Comment